244 related articles for article (PubMed ID: 29137714)
21. Immune based therapy for melanoma.
Ancuceanu R; Neagu M
Indian J Med Res; 2016 Feb; 143(2):135-44. PubMed ID: 27121512
[TBL] [Abstract][Full Text] [Related]
22. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic viruses in melanoma.
Robinson C; Xu MM; Nair SK; Beasley GM; Rhodin KE
Front Biosci (Landmark Ed); 2022 Feb; 27(2):63. PubMed ID: 35227006
[TBL] [Abstract][Full Text] [Related]
24. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
25. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
Hoffner B; Iodice GM; Gasal E
Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic viruses as engineering platforms for combination immunotherapy.
Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for thoracic oncology gone viral.
Patel MR
Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
[TBL] [Abstract][Full Text] [Related]
29. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
30. The viral approach to breast cancer immunotherapy.
Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
[TBL] [Abstract][Full Text] [Related]
31. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
32. Cancer-fighting viruses win approval.
Ledford H
Nature; 2015 Oct; 526(7575):622-3. PubMed ID: 26511559
[No Abstract] [Full Text] [Related]
33. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
35. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Workenhe ST; Verschoor ML; Mossman KL
Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
[TBL] [Abstract][Full Text] [Related]
36. Herpes simplex virus oncolytic vaccine therapy in melanoma.
Sivendran S; Pan M; Kaufman HL; Saenger Y
Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
[TBL] [Abstract][Full Text] [Related]
37. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
38. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
[TBL] [Abstract][Full Text] [Related]
39. Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses.
Goldufsky JW; Daniels P; Williams MD; Gupta K; Lyday B; Chen T; Singh G; Kaufman HL; Zloza A; Marzo AL
J Transl Med; 2023 Jul; 21(1):483. PubMed ID: 37468934
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]